Why the study?
Transvenous ICDs are the standard therapy for sudden cardiac death prevention but commonly cause complications related to intracavitary electrodes, leading to the development of S-ICD as an alternative system.
Does Subcutaneous implantable cardioverter-defibrillator (S-ICD) prevent sudden cardiac death in patients at risk?
Does Subcutaneous implantable cardioverter-defibrillator (S-ICD) prevent sudden cardiac death in patients at risk?
S-ICD successfully treated ventricular tachycardia in a small cohort of patients with no mortality over 2.5 years.
Answers are grounded in this paper and cite their sources.
Supports S-ICD VT termination in limited cases without deaths; leaves open SCD prevention efficacy pending larger trials.
Sudden cardiac death is the final event caused in several cases by ventricular arrhythmias. Transvenous implantable cardioverter-defibrillators have been the standard therapy for the prevention of sudden cardiac death. The most frequent complications associated with TV-ICD is related to intracavitary electrodes. S-ICD has been developed as an alternative system. Novel S-ICD device in prevention of SCA was implanted in 8 patients with an average follow up period of 2.5 years. Bleeding and inappropriate shock was reported in one patient. Appropriate shock for ventricular tachycardia was observed in 5 patients. There was no death reported in any of the patients.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: